Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov;44(4):517-524.
doi: 10.1016/j.ucl.2017.07.001.

Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators

Stacy Loeb  1 , Hasan Dani  2
Affiliations
Review

Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators

Stacy Loeb et al. Urol Clin North Am. 2017 Nov.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Urol Clin North Am. 2018 May;45(2):xiii. doi: 10.1016/j.ucl.2018.03.002. Urol Clin North Am. 2018. PMID: 29650144 No abstract available.

Abstract

This article describes markers used for prostate biopsy decisions, including prostrate-specific antigen (PSA), free PSA, the prostate health index, 4Kscore, PCA3, and ConfirmMDx. It also summarizes the use of nomograms combining multiple variables for prostate cancer detection.

Keywords: Biomarkers; Nomograms; Prostate biopsy; Prostate cancer; Prostate-specific antigen.

PubMed Disclaimer

References

    1. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic Review of Complications of Prostate Biopsy. European urology. 2013 Jun 4; - PubMed
    1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014 Dec 6;384(9959):2027–2035. - PMC - PubMed
    1. Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up. Journal of the National Cancer Institute. 2012 Jan 18;104(2):125–132. - PMC - PubMed
    1. Shoag JE, Mittal S, Hu JC. Reevaluating PSA Testing Rates in the PLCO Trial. N Engl J Med. 2016 May 05;374(18):1795–1796. - PubMed
    1. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004 May 27;350(22):2239–2246. - PubMed

Substances